Science behind Nobel winners spawned one of the biggest marketing duels in pharma history
Science behind Nobel winners spawned one of the biggest marketing duels in pharma history
A timeline of key moments in the development of checkpoint inhibitors
A timeline of key moments in the development of checkpoint inhibitors
Real threat to Opdivo’s small-cell chances will come from elsewhere
Real threat to Opdivo’s small-cell chances will come from elsewhere
H Bristol-Myers επενδύει 12 εκατ. στην Compugen για κλινική έρευνα
H Bristol-Myers επενδύει 12 εκατ. στην Compugen για κλινική έρευνα
BMS’ Opdivo Flounders in Phase III Trial for Small Cell Lung Cancer
BMS’ Opdivo Flounders in Phase III Trial for Small Cell Lung Cancer
Nobel Prize in Medicine Awarded to Checkpoint Inhibitor Pioneers
Nobel Prize in Medicine Awarded to Checkpoint Inhibitor Pioneers
Tecentriq sets the bar in small-cell lung cancer
Tecentriq sets the bar in small-cell lung cancer
The top 10 drugmakers of 2024
The top 10 drugmakers of 2024
Genentech’s Tecentriq Continues to Demonstrate Its Potency as a Treatment for Lung Cancer
Genentech’s Tecentriq Continues to Demonstrate Its Potency as a Treatment for Lung Cancer
Πολλά υποσχόμενο το νέο φάρμακο για την ψωρίαση της Bristol-Myers
Πολλά υποσχόμενο το νέο φάρμακο για την ψωρίαση της Bristol-Myers
Can Pfizer and Merck KGaA parlay Bavencio combo data into a kidney cancer win?
Pfizer and Merck KGaA are one step closer to a brand-new market for their immuno-oncology drug Bavencio. The companies reported winning data in a kidney cancer trial, setting them up … Continue Reading Can Pfizer and Merck KGaA parlay Bavencio combo data into a kidney cancer win?
Merck’s Keytruda threatens Pfizer, Merck KGaA’s Bavencio with Merkel cell ‘priority’ tag
Merck’s Keytruda threatens Pfizer, Merck KGaA’s Bavencio with Merkel cell ‘priority’ tag
Top Pharma News of the Week
Bayer and Haplogen collaborate to develop new treatments against pulmonary diseases August 14, 2018 Bayer and Haplogen GmbH, a Vienna-based biotechnology company, have entered into a multi-year research collaboration agreement … Continue Reading Top Pharma News of the Week
Bristol-Myers Squibb’s Opdivo Gets New Approval for Lung Cancer Indication
The U.S. Food and Drug Administration (FDA) gave Bristol-Myers Squibb’s Opdivo (nivolumab) approval for metastatic small cell lung cancer (SCLC) for patients whose cancer has progressed after platinum-based chemotherapy and at least one other type of … Continue Reading Bristol-Myers Squibb’s Opdivo Gets New Approval for Lung Cancer Indication
Merck Takes Lead from Bristol-Myers Squibb for PD-1/PD-L1
In the field of immuno-oncology, the two dominant players are Merck & Company, with Keytruda and Bristol-Myers Squibb Company with Opdivo. PD-1 and PD-L1 are proteins found on cancer cells that allow them … Continue Reading Merck Takes Lead from Bristol-Myers Squibb for PD-1/PD-L1
Bristol-Myers Squibb Reports 11% Increase in Total Revenues for Q2
Bristol-Myers Squibb reported a strong second quarter, with total revenues of $5.7 billion, up 11 percent from the same quarter in 2017, when it reported $5.144 billion. Sales were driven by … Continue Reading Bristol-Myers Squibb Reports 11% Increase in Total Revenues for Q2
